Glenmark Pharma gets USFDA gesture for Tacrolimus capsules

Overview

• Post By : Kumar Jeetendra


• Source: PTI


• Date: 11 Nov,2020

Tacrolimus capsule is an immunosuppressant and can be employed for preventing organ rejection in certain patients after kidney, liver, or heart transplant.

Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus Capsules USP in the strengths of 0.5 mg, 1 mg and 5 mg, Glenmark said in a regulatory filing.

Quoting IQVIA sales data for the 12 months ending September 2020, Glenmark said the Prograf Capsules, 0.5 mg, 1 mg and 5 mg marketplace achieved annual sales of about USD 286.8 million.

Glenmark said current portfolio consists of 166 products authorised for distribution in the US marketplace and 45 abbreviated new drug applications are pending approval together with the USFDA.

Shares of Glenmark Pharma were trading at Rs 479 each scrip on the BSEup 0.94 per cent over the previous close. PTI SVK BAL